Affymetrix and DNA Link Sign Partnership for Forensic Test Development for Human Identification
February 07 2013 - 6:30AM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) and DNA Link, Inc., a Korean
genomics-based biotechnology company, today announced that they
have signed a Powered by AffymetrixTM (PbA) Program agreement in
which DNA Link, Inc. obtains a worldwide license to develop and
commercialize a forensic test for comprehensive human
identification and other diagnostic tests using Affymetrix’
microarray technology and the Korea FDA (KFDA) cleared GeneChip®
System 3000Dx v.2.
AccuID®Chip is a novel SNP marker based array for personal
identification which can be applied to a variety of forensic
samples, including degraded DNA samples. This array utilizes DNA
Link’s unique approach of combining Affymetrix’ target resequencing
array technology and multiplexing PCR technology to genotype
hundreds of SNP markers in a single experiment to obtain high
quality data and a wide variety of information – all with high
throughput and cost efficiency.
Dr. Jong-Eun Lee, CEO of DNA Link, said, “The advantage of using
SNP markers is that they possess lower mutation rate than STR
markers, thus are more stable in terms of inheritance which could
aid parentage testing, kinship analysis, ethnicity, or predicting
phenotypic characteristics. This novel forensic test, AccuID®Chip,
can be used complementarily with existing STR tests and to build a
more comprehensive forensic database. We are pleased to join the
ranks of other PbA Program partners, such as Roche Diagnostics and
Pathwork Diagnostics in adopting the Affymetrix technology.”
“We are very pleased to have DNA Link join our Powered by
Affymetrix program in which we help partners to develop novel
molecular diagnostic tests for personalized healthcare. DNA Link
being our first partner in Korea will also provide our other PbA
partners access to the Korean personalized genomics market,” said
Dara Wright, Vice President, Clinical Applications Marketing at
Affymetrix.
PLEASE NOTE:
AccuID®Chip is not available for in vitro diagnostic use in the
United States.
Affymetrix®, the Affymetrix logo, Powered by Affymetrix™,
GeneChip® and all other trademarks are the property of Affymetrix,
Inc. AccuID®Chip is trademark of DNA Link and all other trademarks
are the property of their respective owners.
SOURCE: Affymetrix, Inc.
About DNA Link, Inc.
DNA Link, Inc. (listed in KOSDAQ market), based in Korea, is a
leading company in genomics, personalized medicine, molecular
diagnostics, and forensics. As a genomics-based biotechnology
company, DNA Link, Inc. has a complete genotyping solution and
resources for large-scale clinical research projects. DNA Link put
DNAGPS (Genomics Personalized Service), consumer genotyping service
on the Korean market in 2010 and plans to enter the China market in
collaboration with SK Chemicals. For further details about DNA
Link, Inc., please visit www.dnalink.com.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies as well as
leading academic, government, and nonprofit research institutes.
More than 48,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,100 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024